Lead, Investor Relations

Amylyx was started in 2013 by two Brown University students who had an ambitious goal: to improve the lives of people with neurodegenerative diseases by addressing the root cause. Their research and close collaboration with the ALS community ultimately resulted in our first commercial product, which is now approved in the U.S. and conditionally approved in Canada.

At Amylyx, we’re bringing together talented people like you who are guided by our values to be Audacious, Curious, Authentic, Engaging and Accountable in the fight against neurodegenerative diseases like, ALS, Alzheimer’s disease, Wolfram Syndrome and others.

Rediscover your purpose and reimagine your career at a company whose founders, mission, and culture are unlike any other in life sciences—in all the best ways.

Recent milestones include:

• The U.S. Food and Drug Administration (FDA) approved RELYVRIO™ in September of 2022
• Health Canada approved ALBRIOZA™ with conditions in Canada in June of 2022
• AMX0035 is currently under review with the European Medicines Agency
• 350 employees globally, with headquarters in Cambridge, MA, US and Amsterdam, the Netherlands -- and growing strong!

THE ROLE

As Lead, Investor Relations reporting to the Head, Investor Relations and Communications, you will serve as a proactive, collaborative strategic partner to the business and lead initiatives to advance our investor engagement program. A successful candidate will be a strong writer with experience in biotech/pharma investor interactions and contribute to helping set and achieve the company’s global IR goals during a period of dynamic growth for the company.

RESPONSIBILITIES

• Support development and execution of investor relations plans and initiatives aligned with corporate goals.
• Develop quarterly and annual results communications, including financial results press releases, annual reports, conference call scripts, key messages, and Q&A, and other documents to communicate Amylyx’ corporate story to investor and analyst audiences.
• Partner with colleagues to prepare documents for filings and disclosures to be compliant with SEC regulations (i.e., 8-Ks, 10-Ks, 10-Qs, proxies); in certain circumstances, lead creation of documents for filings.
• Write and create investor-facing materials, including content for website, presentations for investor meetings, key message and Q&A documents, and press releases; and update as appropriate.
• Partner with leadership and other colleagues to ensure consistency of messaging.
• Engage with the investment community, including healthcare investors, equity research analysts, and investment bankers, and represent Amylyx at events.
• Participate in one-on-one meetings, bus tours, conferences, and non-deal roadshows, and lead follow-up as appropriate.
• Respond to requests for information from external stakeholders, including shareholders, in a timely manner.
• Partner with executive assistant who manages active IR calendar/schedules and prepares background information on investors in advance of meetings; assist with scheduling and preparations when needed.
• Review and analyze analyst research and models, communication trends and best practices, consensus estimates, peer estimates, industry trends, competitive landscape, sell-side research, and market-related trends impacting valuation and perception; summarize market sentiment on Amylyx and peers.
• Support the overall Investor Relations function, including assisting with day-to-day needs and long-term special projects.

REQUIREMENTS

• Bachelor’s degree
• 10+ years of relevant work experience, with at least 5+ years of previous experience in the biotech/pharma industry.
• Investor Relations, Corporate Finance, Equity Research, Buy-Side, or Consulting experience preferred.
• Managing the full life cycle of multiple projects, from strategy and development to deployment and evaluation.
• A clear and thorough understanding of the financial modeling techniques used by analysts to project a company's operating and financial performance and the resulting value for its stock.
• Exceptional verbal, written, and presentation skills, with the ability to effectively tailor communication to a broad collection of external and internal audiences.
• Ability to translate complex scientific, clinical, and financial data into easy to communicate messaging.
• A strong understanding of investors' needs and priorities.
• Exceptional attention to detail and ability to multi-task in a fast-paced, high-pressure, deadline driven environment.
• Knowledge of SEC regulatory requirements and disclosures; understanding sensitivity around material non-public information.
• Ab